Applied BioCode (TPE:6598) ROCE % : -25.29% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Applied BioCode ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Applied BioCode's annualized ROCE % for the quarter that ended in Dec. 2024 was -25.29%.

Applied BioCode ROCE % Historical Data

The historical data trend for Applied BioCode's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied BioCode ROCE % Chart

Applied BioCode Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-11.29

-15.40

-17.46

-16.00

-26.24

Applied BioCode Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-3.38	-28.89	-23.76	-31.02	-25.29

Applied BioCode ROCE % Calculation

Applied BioCode's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-259.354	/	( ( (993.207 - 101.564)	+	(1214.902 - 129.83) )	/ 2 )
	=	-259.354	/	( (891.643	+	1085.072)	/ 2 )
	=	-259.354	/	988.3575
	=	-26.24 %

Applied BioCode's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-282.296	/	( ( (1247.212 - 99.886)	+	(1214.902 - 129.83) )	/ 2 )
	=	-282.296	/	( ( 1147.326	+	1085.072 )	/ 2 )
	=	-282.296	/	1116.199
	=	-25.29 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Applied BioCode (TPE:6598) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Applied BioCode ROCE % Related Terms

Thank you for viewing the detailed overview of Applied BioCode's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied BioCode Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Applied BioCode Corp (TPE:6598) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

12130 Mora Dr., Unit 2,, Santa Fe Springs, CA, USA, 90670

Website

https://www.apbiocode.com

Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.

Applied BioCode Headlines

No Headlines